Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on inflammatory diseases. Its principal program is rademikibart, an antibody designed to target interleukin-4-receptor alpha, with company updates centered on asthma, chronic obstructive pulmonary disease and moderate-to-severe atopic dermatitis.
Recurring news includes rademikibart clinical data, Seabreeze STAT asthma and COPD study updates, Data Monitoring Committee and regulatory-related disclosures, partner activity involving Simcere in China, financial results, financing activity, investor conference participation and governance matters.
Connect Biopharma (Nasdaq: CNTB) reported positive topline Phase 1 results for IV rademikibart (300 mg 2-minute IV push) in asthma and COPD patients on March 30, 2026. Patients showed rapid FEV1 gains (≥200 mL in many) within 15 minutes, with mean improvements ~200–400 mL maintained through Day 29. The drug was generally well tolerated with no serious or severe AEs. Connect is recruiting Phase 2 Seabreeze STAT studies for acute exacerbations and expects topline Phase 2 data mid-2026, then plans FDA discussions on a Phase 3 program.
Connect Biopharma (Nasdaq: CNTB) announced that results from a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis, conducted by partner Simcere, will be presented in the Late-Breaking Research session at the AAD Annual Meeting on March 28, 2026.
The presentation (RADIANT-AD) is scheduled for March 28, 2026, 9:48–10:00 a.m. MDT at Bellco Theatre 3. According to Connect Biopharma, the Phase 3 data provide a strong basis for Simcere’s pending NDA in China and highlight rademikibart’s potentially differentiated safety and efficacy, supporting future AD development outside China.
Connect Biopharma (Nasdaq: CNTB) management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:00 a.m. ET.
A live webcast will be available via the company investor website and an archived replay will remain accessible for approximately 90 days.
Connect Biopharma (Nasdaq: CNTB) management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET.
A live webcast will be available via the Investors section of the company website at investors.connectbiopharma.com, with an archived replay accessible for approximately 90 days after the conference.
Connect Biopharma (Nasdaq: CNTB) highlighted new mechanism‑of‑action data for rademikibart and outlined 2026 priorities, emphasizing clinical execution. Mechanistic studies show enhanced IL‑4R binding, greater internalization versus dupilumab, and stronger rescue of β‑agonist responsiveness in human airway models, supporting faster, larger FEV1 improvements observed previously. Ongoing Phase 1b IV study has shown preliminary faster FEV1 increases versus subcutaneous dosing with topline results expected in Q1 2026. Phase 2 Seabreeze STAT asthma and COPD trials are recruiting with topline data expected mid‑2026. Cash, cash equivalents and short‑term investments were $54.8M as of Sept 30, 2025, with runway into 2027 under current plans.
Connect Biopharma (Nasdaq: CNTB) announced that company management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 10:50 a.m. ET.
A live webcast will be available via the company's Investors website at investors.connectbiopharma.com, and an archived replay will be accessible on the site for approximately 90 days after the conference.
Connect Biopharma (Nasdaq: CNTB) reported third quarter 2025 results and a business update on Nov 12, 2025. Key developments include ongoing recruitment in Phase 2 Seabreeze STAT studies for acute asthma and COPD with topline data expected in 1H 2026, and presentation of positive Phase 2 asthma data at ERS 2025 showing larger lung-function gains in patients with baseline EOS ≥300 cells/μL and FeNO ≥25 ppb. Connect’s Greater China licensee, Simcere, had its NDA for rademikibart in atopic dermatitis accepted by China’s NMPA in July 2025; Connect is eligible for up to $110 million of remaining milestone payments plus tiered royalties. Corporate actions included terminating the ADR program and directly listing ordinary shares on Nasdaq under CNTB. Cash and short-term investments were $54.8M at Sept 30, 2025, expected to fund operations into 2027.
Connect Biopharma (NASDAQ:CNTB) presented promising data for rademikibart, their investigational anti-IL-4Rα antibody, at the European Respiratory Society Congress 2025. The Phase 2b trial results showed significant improvements in lung function and asthma control, particularly in patients with elevated type 2 inflammatory markers.
Key findings include a 507 mL improvement in prebronchodilator FEV1 at Week 24 in patients with high EOS and FeNO levels, and substantial reductions in asthma exacerbations (63% reduction in high EOS patients and 69% reduction in high FeNO patients). The company expects to report topline data from ongoing Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD in 1H 2026.
Connect Biopharma (Nasdaq: CNTB) announced two poster presentations at the upcoming European Respiratory Society (ERS) Congress 2025, scheduled for September 27 - October 1, 2025, in Amsterdam and virtually. Both presentations focus on Rademikibart, the company's treatment for asthma.
Dr. Raúl Collazo will present research on Rademikibart's effectiveness in moderate-to-severe asthma and its impact on FEV1 improvements in Type 2 Asthma. The presentations will take place on September 29th at 8:00 a.m. CET during Session #218 on Biologics for Asthma and Allergic Rhinitis. The presentations will later be available on Connect's website.
Connect Biopharma (Nasdaq: CNTB), a clinical-stage biopharmaceutical company, has completed the termination of its ADR program and transitioned to directly listing its ordinary shares on the Nasdaq Global Market. The company's ADRs were mandatorily cancelled and exchanged for ordinary shares at a one-for-one ratio on September 2, 2025.
Under the leadership of CEO Barry Quart, Connect Biopharma is positioning itself as a U.S.-centric company, focusing on developing treatments for asthma and COPD. The company is currently executing Phase 2 Seabreeze STAT studies for its drug candidate rademikibart, aiming to strengthen its relationship with U.S. investors and enhance shareholder value.